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Abstract
A 25 yr old 60 kg haemoglobin SS male presented with a 3 year history of a discharging sinus in the
left upper arm. His last crisis was ten years earlier; while his stable haemoglobin concentration was
10 g/dl.
Examination revealed healthy looking, well hydrated man. He had left upper arm chronic
osteomyelitis which was diagnosed radiologically. He was scheduled for an elective saucerization
and sequestrectomy. Tourniquet was applied to reduce blood loss and maintain a relatively
bloodless field at surgery; and nitrous oxide/oxygen/halothane relaxant technique of anaesthesia
was adopted.
No perioperative problems were encountered and the patient made remarkable improvement and
was discharged home. At post surgical review a few weeks after, he was stable and well.
Introduction
Sickle cell disease is a family of haemoglobin disorders
with autosomal dominance inheritance [1] the beta chain
of haemoglobin has valine substituted for glutamine in
position 6 of the normal adult haemoglobin.
Generally, sickle cell disease is found in Negroes and non-
Negroes race in the African continent, Mediterranean and
in parts of India. The prevalence in Nigeria is about 0.4-
3%[2]. In the homozygous form, red blood cells lose their
normal morphology and become sickle-shaped if they are
exposed to hypoxia, acidosis, low temperature or cellular
dehydration [3]
Anaesthesia for homozygous sickle cell patients can be
very challenging. The anaesthetist is confronted with the
problems of anaemia, which may necessitate reduction of
intra-operative blood loss by the application of tourni-
quet (which on its own pre-disposes the patient to a sickle
cell crisis).
Case report
E.I. a 25 yr old sickler, weighing 60 kg, presented in the
orthopaedic clinic with a 3-year history of discharging
sinus in his left upper arm. He was diagnosed as a sickle
cell (Hb SS) patient many years earlier though his physical
features were not suggestive of haemoglobin SS disease.
The last episode of a crisis was 10 yrs before presentation.
His pulse rate was 100 beats/minute, regular with normal
volume. While the blood pressure was 120/80 mmHg
[26/10.7 Kpa]. The heart sounds were normal. His packed
cell volume was 30%. Kidney and liver function tests were
essentially normal. The X-ray of the left arm showed cir-
cumscribed areas of increased radiodensity; with areas of
increased radioluscency in the middle third of left
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humerus-suggestive of osteomyelitis. He has had Ampi-
clox capsules and Erythromycin tablets at different times
since the onset of symptoms. His airway was assessed, as
Mallam pati I while the anaesthetic risk assessment was
ASA II. His premedication drug was oral diazepam (10
mg) at night and 10 mg on morning of surgery, and he
was generally calm at induction. Monitors attached to the
patient were pulse oximeter, thermocouple and a sphyg-
momanometer. The urine output was monitored with
urethral catheter and bag.
500 mls of warm normal saline was infused before induc-
tion of anaesthesia. The patient was pre-oxygenated for 5
minutes. 15 mg of pentazocine was given along with 8
mgs of pancuronium (as a mega dose) to shorten time of
endotracheal intubation. Suxamethonium was not used.
300 mg of thiopentone was given in divided doses of 100
mg over 90 sec from the point of administration of pan-
curonium, for induction of anaesthesia. He was ventilated
by a facemask with 100% oxygen using Malpeson A
breathing system. On full muscle relaxation, the trachea
was intubated with a size 8.00 mmID polyvinyl endotra-
cheal tube and connected to a closed circuit with soda
lime absorber. The lungs were manually ventilated using
intermittent positive pressure ventilation with 50%
nitrous oxide and oxygen in 0.5% of halothane
Further, his body was well covered to minimize heat loss.
Vital signs remained relatively stable with monitoring of
temperature, pulse rate, blood pressure and oxygen satu-
ration. The tourniquet time was 1 hour. Blood loss was
500-mls and 2 litres of warms crystalloids were given to
the patient for replacement and fluid maintenance. Oxy-
gen saturation was 99-100% throughout the surgery and
urine output was adequate.
At the end of surgery, residual muscle relaxation was
reversed safely. The patient was transferred to the recovery
room. The patient had supplemental oxygen for 24 hours
at a rate of 5 liters min-1 by facemask. Fluid intake was 1
litre of 4.3% dextrose saline, alternating with 1 litre of 5%
dextrose 8 hourly over 24 hours. Analgesia was provided
with pentazocine 30 mg i.m 8 hourly for 48 hours. This
was followed by diclofenac sodium and 500 mg of oral
Cefuroxime for 10 days.
He was discharged home, by the 6th postoperative day
with packed cell volume (PCV) of 28%; on haematinics.
Discussion
In sickle cell (homozygote SS), the abnormal gene is due
to substitution of valine for glutamic acid at position 6 of
the beta-chain of haemoglobin A. 90% of haemoglobin in
the red blood cell of the homozygote SS is S[1]. Haemo-
globin S is vulnerable to low oxygen tension. At 5.3 Kpa
(40 mmHg), the reduced haemoglobin forms complex
strands called 'tactoids" which distort the red cells to form
the characteristic sickle shape. The molecular basis of this
is aggregation of oxygenated haemoglobin molecules
along their longitudinal axis [4]. Sickle cells are fragile,
and haemolyse; they also block small vessels resulting in
infarction. The resultant cell death and tissue infarction at
the site of obstruction is termed a sickle cell crisis.
Although some sicklers are asymptomatic, possibly due to
their ability to maintain a higher than normal haemo-
globin F throughout their lives, majority are not so fortu-
nate. Many episodes of sickling may occur spontaneously,
although certain factors may increase the risk [2]. Such
factors include hypoxia, hypothermia, tourniquets, dehy-
dration, acidosis, circulatory stasis and pyrexia. Patients
with sickle cell disease usually have an associated history
of poor development and failure to thrive. Sickling and
microvascular occlusion within bones and epiphyseal
plates often predispose such patients to limb shortening,
joint deformity and osteomyelitis (as was occasioned in
the patient) Chronic osteomyelitis was diagnosed based
on the clinical features and was confirmed radiologically.
In Nigeria, sickle cell patients may be accepted for surgery
with a haemogbolin of 6-10 gm.dL-1 [5] however, in the
Western world the story is not the same. Although it is
accepted that preoperative transfusion can be avoided in
sicklers having low risk surgery, the recommendation is
that transfusion should be done for high risk surgery [6].
Low risk surgery, applies to procedures not associated
with significant blood loss while high risk surgery implies
procedures associated with a potential for significant
blood loss. Procedures on the bone tend to bleed intraop-
eratively and ooze postoperatively because homeostasis
may be difficult, thus suggesting that sequestrectomy is a
potential high risk surgery.
Hypovolaemia must be avoided to prevent dehydration,
hyperosmolality and increased viscosity, by giving intra-
venous fluid therapy during the period of preoperative
starvation. Goodwin [7] suggested preoperative hydration
for at least 8 hours of intravenous fluids for high risk cases
and either intravenous hydration or oral hydration with
clear fluids until 3-4 hours preoperatively for low risk
cases [7]. The patient received a maintenance dose of 4
ml.kg-1 hr-1 of 5% dextrose in saline over 6 hours (about
1 litre of fluids
Desired monitoring should include pulse oximetry, tem-
perature, urine output and the state of hydration with a
central venous line. Blood pressure measurement, electro-
cardiogram and tidal carbon dioxide are also desirable. In
the absence of most of these equipments, those availableCases Journal 2009, 2:9085 http://www.casesjournal.com/content/2/1/9085
Page 3 of 3
(page number not for citation purposes)
appeared to suffice. Adequate draping and use of warmed
fluids were applied to reduce hypothermia.
In the event of hypotension developing introperatively,
plasma volume expanders may be used for treatment. In
sicklers, crystalloids should be used with caution because
of the risk of fluid overload avoided except in resistant
cases of hypotension where small doses should be used to
avoid the exacerbation of a crisis [8]. Supplemented oxy-
gen (100%) by facemask was given intraoperatively to
improve the patient's oxygen content to reduce the inci-
dence of sickling. This extended into the postoperative
period
A tourniquet was used intraoperatively to further guaran-
tee minimal blood loss. Controversies govern the use of
tourniquets. It has been reported that the use of tourni-
quets may produce local stasis and acidosis which may
enhance sickling [9]. Also, Oginni in his study noted a sig-
nificantly higher incidence of complications in sickle cell
patients than in a normal group[10]; while other workers
have concluded that prolonged use of tourniquets in
patients with sickle cell disease is safe, provided that opti-
mum acid - base status and oxygenation are maintained
throughout the procedure [11,12];. Facilities for blood
analysis were not available in this patient. Where acidosis
occurs, a period of hyperventilation or administration of
sodium bicarbonate prior to release of tourniquet may be
sufficient[1].
Although autologous blood transfusion is now possible
with the use of intraoperative cell saver for patients with
sickle cell disease [12], this patient was not considered for
such a procedure because the blood lost was infected with
sequestrum. Blood was not transfused during surgery as
the patient's blood loss 500 ml, was thought to be mod-
est. Oxygen therapy was not continued beyond the first 24
hours postoperatively. While it was beneficial in prevent-
ing postoperative hypoxia, its continuous use may cause
depression of erythropoiesis, so that anaemia is worsened
later [1].
Parenteral pentazocine 0.6 mg.kg-1 (30 mg) in 8 hourly
over 48 hours appeared to suffice without any associated
cardio respiratory depression. This was followed up with
diclofenac orally and topical piroxicam to achieve ade-
quate analgesia. In the post operative period, adequate
hydration and analgesia was maintained to prevent vaso-
occlusive crisis. Postoperative vaso-occlusive crisis have
been associated with 12% mortality [13]. Postoperative
antibiotics were also given to treat infection and reduce
the likelihood of sickling.
Conclusion
Sickle cell disease is associated with chronic anaemia and
a predilection to crisis development. Avoidance of stress
producing factors like dehydration, hypoxia, hypother-
mia, acidosis, circulatory stasis and pyrexia are helpful in
reducing crisis rate. The use of tourniquet is still contro-
versial. Careful preoperative preparation and anaesthesia
lead to a successful outcome in most circumstances.
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